Rights issue in Oasmia Pharmaceutical AB (SE) — SEK 176 million

Carnegie acted as sole financial adviser in the rights issue of 9.8 million new shares at a subscription price of SEK 18 per share. Oasmia develops novel formulations of already established cytostatics for both human and veterinary use, which, in comparison to current alternatives, show improved performance, a reduced side-effect profile and an expanded therapeutic area.December 2014.